282 related articles for article (PubMed ID: 28237404)
1. Pharmacogenetics in cardiovascular diseases: State of the art and implementation-recommendations of the French National Network of Pharmacogenetics (RNPGx).
Lamoureux F; Duflot T;
Therapie; 2017 Apr; 72(2):257-267. PubMed ID: 28237404
[TBL] [Abstract][Full Text] [Related]
2. Clinical application of cardiovascular pharmacogenetics.
Voora D; Ginsburg GS
J Am Coll Cardiol; 2012 Jul; 60(1):9-20. PubMed ID: 22742397
[TBL] [Abstract][Full Text] [Related]
3. Pharmacogenetics and cardiovascular disease--implications for personalized medicine.
Johnson JA; Cavallari LH
Pharmacol Rev; 2013 Jul; 65(3):987-1009. PubMed ID: 23686351
[TBL] [Abstract][Full Text] [Related]
4. Cardiovascular Pharmacogenomics--Implications for Patients With CKD.
Cavallari LH; Mason DL
Adv Chronic Kidney Dis; 2016 Mar; 23(2):82-90. PubMed ID: 26979147
[TBL] [Abstract][Full Text] [Related]
5. Expanding role of pharmacogenomics in the management of cardiovascular disorders.
Yip VL; Pirmohamed M
Am J Cardiovasc Drugs; 2013 Jun; 13(3):151-62. PubMed ID: 23579966
[TBL] [Abstract][Full Text] [Related]
6. Pharmacogenomics implementation in cardiovascular disease in a highly diverse population: initial findings and lessons learned from a pilot study in United Arab Emirates.
Al-Mahayri ZN; Khasawneh LQ; Alqasrawi MN; Altoum SM; Jamil G; Badawi S; Hamza D; George L; AlZaabi A; Ouda H; Al-Maskari F; AlKaabi J; Patrinos GP; Ali BR
Hum Genomics; 2022 Sep; 16(1):42. PubMed ID: 36154845
[TBL] [Abstract][Full Text] [Related]
7. Pharmacogenetics of vitamin K antagonists: useful or hype?
Lippi G; Franchini M; Favaloro EJ
Clin Chem Lab Med; 2009; 47(5):503-15. PubMed ID: 19397481
[TBL] [Abstract][Full Text] [Related]
8. Pharmacogenetics of clopidogrel and warfarin in the treatment of cardiovascular diseases: an overview of reviews.
de Lara DV; de Melo DO; Araújo Silva LC; Gonçalves TS; Júnior Lima Santos PC
Pharmacogenomics; 2022 May; 23(7):443-452. PubMed ID: 35380455
[TBL] [Abstract][Full Text] [Related]
9. Pharmacogenetic Foundations of Therapeutic Efficacy and Adverse Events of Statins.
Arrigoni E; Del Re M; Fidilio L; Fogli S; Danesi R; Di Paolo A
Int J Mol Sci; 2017 Jan; 18(1):. PubMed ID: 28067828
[TBL] [Abstract][Full Text] [Related]
10. 3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins) and genetic variability (single nucleotide polymorphisms) in a hepatic drug uptake transporter: what's it all about?
Kim RB
Clin Pharmacol Ther; 2004 May; 75(5):381-5. PubMed ID: 15116050
[No Abstract] [Full Text] [Related]
11. Applied pharmacogenomics in cardiovascular medicine.
Weeke P; Roden DM
Annu Rev Med; 2014; 65():81-94. PubMed ID: 24111889
[TBL] [Abstract][Full Text] [Related]
12. Genotype-guided coumarin dosing: where are we now and where do we need to go next?
Baranova EV; Verhoef TI; Asselbergs FW; de Boer A; Maitland-van der Zee AH
Expert Opin Drug Metab Toxicol; 2015 Apr; 11(4):509-22. PubMed ID: 25595525
[TBL] [Abstract][Full Text] [Related]
13. Pharmacogenomics and drug toxicity.
Nakamura Y
N Engl J Med; 2008 Aug; 359(8):856-8. PubMed ID: 18650508
[No Abstract] [Full Text] [Related]
14. [Pharmacogenetics and interindividual variability in drug response: cytochrome P-450 2C9 and coumarin anticoagulants].
Becquemont L; Verstuyft C; Jaillon P
Bull Acad Natl Med; 2006 Jan; 190(1):37-49; discussion 50-3. PubMed ID: 16878445
[TBL] [Abstract][Full Text] [Related]
15. [Pharmacogenetics of indirect anticoagulants: value of genotype for improvement of efficacy and safety of therapy].
Sychov DA; Kropacheva ES; Ignat'ev IV; Bulytova IuM; Dobrovol'skiĭ AB; Panchenko EP; Kukes VG
Kardiologiia; 2006; 46(7):72-7. PubMed ID: 16883270
[TBL] [Abstract][Full Text] [Related]
16. [Genetic determinants of response to vitamin K antagonists].
Mundi S; Distante A; De Caterina R
G Ital Cardiol (Rome); 2014 Sep; 15(9):482-93. PubMed ID: 25298357
[TBL] [Abstract][Full Text] [Related]
17. Oral anticoagulants: Pharmacogenetics Relationship between genetic and non-genetic factors.
D'Andrea G; D'Ambrosio R; Margaglione M
Blood Rev; 2008 May; 22(3):127-40. PubMed ID: 18234403
[TBL] [Abstract][Full Text] [Related]
18. A European Spectrum of Pharmacogenomic Biomarkers: Implications for Clinical Pharmacogenomics.
Mizzi C; Dalabira E; Kumuthini J; Dzimiri N; Balogh I; Başak N; Böhm R; Borg J; Borgiani P; Bozina N; Bruckmueller H; Burzynska B; Carracedo A; Cascorbi I; Deltas C; Dolzan V; Fenech A; Grech G; Kasiulevicius V; Kádaši Ľ; Kučinskas V; Khusnutdinova E; Loukas YL; Macek M; Makukh H; Mathijssen R; Mitropoulos K; Mitropoulou C; Novelli G; Papantoni I; Pavlovic S; Saglio G; Setric J; Stojiljkovic M; Stubbs AP; Squassina A; Torres M; Turnovec M; van Schaik RH; Voskarides K; Wakil SM; Werk A; Del Zompo M; Zukic B; Katsila T; Lee MT; Motsinger-Rief A; Mc Leod HL; van der Spek PJ; Patrinos GP
PLoS One; 2016; 11(9):e0162866. PubMed ID: 27636550
[TBL] [Abstract][Full Text] [Related]
19. Pharmacogenetics of antidepressant drugs: State of the art and clinical implementation - recommendations from the French National Network of Pharmacogenetics.
Quaranta S; Dupouey J; Colle R; Verstuyft C
Therapie; 2017 Apr; 72(2):311-318. PubMed ID: 28237405
[TBL] [Abstract][Full Text] [Related]
20. [Oral anticoagulation and pharmacogenetics: importance in the clinical setting].
Benusiglio PR; Desmeules J; de Moerloose P; Dayer P
Rev Med Suisse; 2007 Sep; 3(124):2030, 2033-4, 2036. PubMed ID: 17955831
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
